Abcam to participate in the Morgan Stanley 20th Annual Global Healthcare Conference

On September 1, 2022 Abcam plc (Nasdaq: ABCM; AIM: ABC) ("Abcam" or the "Company"), a global leader in the supply of life science research tools, reported that Alan Hirzel, Chief Executive Officer, will be participating in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare conference at the Sheraton, New York Hotel in New York at approximately 4.10 p.m. BST (11.10 a.m. EDT) on 14 September 2022 (Press release, Abcam, SEP 1, 2022, View Source [SID1234618884]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the webcast, please use the following link:

View Source

The live audio webcast will also be available in the investor section of Abcam’s corporate website at corporate.abcam.com/investors/reports-presentations/. An archive will be available after the call at that same address.

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

On September 1, 2022 ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, reported that management will participate in the following investor conferences in September (Press release, ORIC Pharmaceuticals, SEP 1, 2022, View Source [SID1234618883]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi’s 17th Annual Biopharma Conference – Targeted oncology panel discussion on Thursday, September 8, 2022, at 2:40 p.m. ET

Wells Fargo Healthcare Conference – Participating in fireside chat on Friday, September 9, 2022, at 8:35 a.m. ET

H.C. Wainwright 24th Annual Global Investment Conference – Presenting company overview on Monday, September 12, 2022, at 7:00 a.m. ET
Webcasts of the panel discussion and presentations will be available through the investor section of the company’s website at www.oricpharma.com. Replays of webcasts will be available for 90 days following the events.

Delcath Systems to Participate at the H.C. Wainwright 24th Annual Global Investor Conference on September 12 and 13, 2022

On September 1, 2022 Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, reported that it will participate at the H.C. Wainwright 24th Annual Global Investor Conference (Press release, Delcath Systems, SEP 1, 2022, View Source [SID1234618880]). Delcath CEO, Gerard Michel will present on September 12 at 8:30 AM ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. (PRNewsfoto/Delcath Systems, Inc.)

A webcast of the presentation will be available at View Source A replay of the presentation will be available following the event.

Management is scheduled to host one-on-one meetings throughout the event. Investors interested in arranging one-on-one meetings should contact your conference representative. You may also call or email Ben Shamsian of Lytham Partners at 646-829-9701, or [email protected].

Gritstone to Participate in Two Upcoming Investor Conferences

On September 1, 2022 Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, reported that management will present at the 2022 Wells Fargo Healthcare Conference, taking place September 7-9, 2022, in Boston, MA, and participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference, taking place September 12-14, 2022, in New York, NY (Press release, Gritstone Oncology, SEP 1, 2022, View Source [SID1234618879]). The events will also be available via webcast. Please find additional details about the events below.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2022 Wells Fargo Healthcare Conference
Presentation Date: Thursday, September 8, 2022, 1:20pm EDT
Presenters: Celia Economides, Chief Financial Officer and Matthew J. Hawryluk, Chief Business Officer
Location: Boston, MA
Webcast: View Source

H.C. Wainwright 24th Annual Global Investment Conference
Fireside Chat Date: Tuesday, September 13, 2022, 3:30pm EDT
Participant: Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive Officer
Location: New York, NY
Webcast: View Source

The events will be accessible via the Investors & Media section of the company’s website at View Source Archived replays will be accessible for 30 days following the events.

Ultragenyx to Participate at Citi BioPharma Conference

On September 1, 2022 Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, reported that Eric Crombez, Chief Medical Officer, Gene Therapy, will participate in a Rare Disease Panel at Citi’s 17th Annual BioPharma Conference on Wednesday, September 7, 2022, at 11:20 AM ET (Press release, Ultragenyx Pharmaceutical, SEP 1, 2022, View Source [SID1234618878]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live and archived webcast of the presentation will be accessible from the company’s website at View Source The replay of the webcast will be available for 90 days.